Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3331 Outcomes of upfront treatment with mFOLFIRINOX regimen in G3 GEP-NENs: A monocentric retrospective experience

Introduction: To date outcomes of standard chemotherapy are not homogeneous in different subgroups of G3 GEP-NENs and remain unsatisfactory and poor; new therapeutic options are desirable in this setting.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Borghesani M

Authors: Borghesani M, Reni A, Zaninotto E, Fumagalli A, Benini L,

Keywords: net, mfolfirinox, chemotherapy, g3, minen,

#3250 High TMB and MSI-high as independent predictors of survival in NENs

Introduction: To date, there are no validated molecular biomarkers for personalized therapy in NENs. Tumor genome sequencing may help unravel NEN molecular landscape and identify novel targets for an individualized approach.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: La Salvia A, Barroso G, Espinosa Olarte P, Anton Pascual B, Modrego Sanchez A,

Keywords: molecular profiling, neuroendocrine neoplasm, TMB, microsatellite instability (MSI)/mismatch repair deficiency (MMRd) status, prognosis,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia

Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bottiglieri F, Modica R, de Cicco F, Minotta R, Faggiano A,

Keywords: gastric, neuroendocrine, type1, type3, metastases,

#2809 Sporadic Neuroendocrine Neoplasms in Young Adult Patients: Natural History, Prognosis and Management

Introduction: Data specific to sporadic neuroendocrine neoplasms (NEN) in young adult patients (pts) are limited due to its rare occurrence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Altieri B

Authors: Altieri B, Modica R, Bottiglieri F, de Cicco F, Faggiano A,

Keywords: neuroendocrine neoplasms, young patients, age, natural history, treatment, prognosis,